Log In
BCIQ
Print this Print this
 

SD-101

Also known as: HCV Therapy

  Manage Alerts
Collapse Summary General Information
Company Dynavax Technologies Corp.
DescriptionImmunostimulatory sequence (ISS)-based second-generation type C toll-like receptor 9 (TLR9) agonist
Molecular Target Toll-like receptor 9 (TLR9)
Mechanism of ActionToll-like receptor 9 (TLR9) agonist
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/01/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today